None listed
Conditions
Interventions
Drug : Patiant needs to take Hyenggaelong Granule(HANPOONG PHARM & FOODS Co.) 3g orally 3 times a day before or during meals for 4 weeks
Sponsors
Kyung Hee University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients who are diagnosed by moderate level of allergic rhinitis for more than 8 weeks - At least one of the following conditions: Nasal congestion, rhinorrhea, sneeze, pruritus - At least one of the following Moderate abnormality conditions: sleep disturbance; daily activity, physical exercise, leisure activity limitations; work/school work limitations; discomfort with several symptoms 2) Age > 19 3) Able to dialogue 4) Agree with informed consent
Exclusion criteria
Exclusion criteria: 1) Patients who are taken one of the following drugs for treating Rhinitis or acute upper respiratory infections etc * Drugs which determined to have negative effect on symptoms of rhinitis or skin prick test (oral or nasal) ? Short acting anti-histamines / H1 blockers (drug use within lase 1 week) ? Long acting anti-histamines / H1 blockers (drug use within lase 2 week) ? Corticosteroids (drug use within lase 1 month) ? Anti-cholinergic drug (drug use within lase 1 week) ? Anti-leukotriene drug (drug use within lase 1 week) ? Decongestants (drug use within lase 1 week) ? Tricyclic antidepressants, phenothiazines (drug use within lase 2 week) ? Non-steroidal analgesics (drug use within lase 1 week) ? Drugs that is judged to be inappropriate for the trial by the researchers 2) Used Korean medicine for treating rhinitis within last 7 days 3) Patients who has severe disease, such as malignant tumor, severe dyslipidemia, liver or kidney dysfunction, anemia, active pulmonary tuberculosis, infection or systemic disease etc 4) Presence of internal nasal obstruction or nasal deformities or history of nasal surgery within 2 months 5) History of active respiratory disease(ex. asthma) 6) Hypertension or Diabetes 7) Experienced immunotherapy or systemic steroid treatments within last 3 months 8) Experienced drug allergic reactions 9) Experienced anaphylactic reactions, during allergen test 10) Female patients who are pregnant or lactating or have the chances of pregnancy 11) Patients who are participated other clinical trials within last 1 month 12) Patients who are unable to participate the trial (paralysis, severe mental or psychological illness, dementia, drug addiction, unable to make to participate in the trial, severe visual or auditory dysfunction, unable to visit hospital regularly, unable to communicate through spoken or written Korean etc) 13) Patients who are judged to be inappropriate for the clinical study by the researchers
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total nasal symptom score (TNSS) ;pre KiFDA-AR ver 2.0 | — |
Secondary
| Measure | Time frame |
|---|---|
| Skin prick test;Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ);Pattern Diagnosis by Doctor of Korean Medicine;Cold-heat Pattern Identification Questionnaire;Total Immunoglobulin E;Heart Rate Variability;Ryodoraku Objectives;Waters, Caldwell, and lateral view (paranasal sinus 3P) X-ray ;Perceived Stress Scale;Eosinophil count | — |
Countries
Korea, Republic of
Contacts
Public ContactMinhee Kim
Kyung Hee University Oriental Medicine Hospital at Gangdong
Outcome results
None listed